CA2021942C - Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent - Google Patents
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent Download PDFInfo
- Publication number
- CA2021942C CA2021942C CA002021942A CA2021942A CA2021942C CA 2021942 C CA2021942 C CA 2021942C CA 002021942 A CA002021942 A CA 002021942A CA 2021942 A CA2021942 A CA 2021942A CA 2021942 C CA2021942 C CA 2021942C
- Authority
- CA
- Canada
- Prior art keywords
- daunorubicin
- glutaraldehyde
- antibody
- conjugate
- doxorubicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention relates to antitumor compounds of the formula I:
(see formula I) wherein M is selected from the group consisting of an hydrogen atom, a peptide residue, and a protein residue linked to the carbon atom via the amino residue of .epsilon.-lysine present therein which can be an antibody used to target the anti-tumor agent to the malignant cells, and R can be an antitumor agent such as daunorubicin, doxorubicin, or an epirubicin derivative.
(see formula I) wherein M is selected from the group consisting of an hydrogen atom, a peptide residue, and a protein residue linked to the carbon atom via the amino residue of .epsilon.-lysine present therein which can be an antibody used to target the anti-tumor agent to the malignant cells, and R can be an antitumor agent such as daunorubicin, doxorubicin, or an epirubicin derivative.
Description
2~~~.94~
TITLE OE THE INVENTION
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent.
BACKGROUND OI~ THE IN~IENTION
Chemotherapeutic agents currently used for antitumour therapy are selected for their toxicity towards rapidly proliferating cells. Most of them cause undesirable systemic effects such as cardiac or renal toxicity, marrow aplasia, alopecia, nausea and vomiting.
During the last few years, many authors have tried to eliminate these 1 0 side effects by increasing the availability of the drug to the tumour site. Enzymes, radioisotopes, DNA, toxins, various macxomolecules, and antibodies against fibrin or against tumour-specific surface antigens were bound to drugs in an attempt to increase the selectivity of the chemotherapeutic agents, or to decrease their toxic effects on 1 5 normal cells ~Rubens R.D., hancet, 2 1974, pp.498-499; Gregoriadis G.
et al., Res. Commun.Chem. 1'athol. Pharm., TO, 1977, pp.351-362).
The targeting of drugs to a tumour by antibodies to surface antigens may have considerable implications by increasing the therapeutic index.
2 0 It is recognized that the ideal antineopiastic drug would destroy cancer cells without adverse effects or toxicities on normal cells, but no such drug exists. I-Towever, despite the narrow therapeutic index of many drugs, treatment and even cure are possible in some patients.
Dactinomycin, doxorubicin and daunorubicin are all given 2 5 rapidly intravenously and all cause tissue necrosis if extravasation occurs. When doxorubicin and daunorubicin are given rapidly intravenously, there is rapid dispersement throughout tissues and plasma. The r7 t1/2 is 30 min, with detectable plasma levels of doxorubicin up to 15 h. Both doxorubicin and daunorubicin are extensively metabolized by the liver, yielding active and inactive metabolites.
Dactinomycin, doxorubicin and daunorubicin have limited antitumor activity. Dactinomycin is effective in testicular carcinoma and sarcomas. Daunorubicin is effective in treating acute leukemia.
1 0 In contrast, doxorubicin is one of the most active antineoplastics ever identified. In fact it is used to treat acute leukemia, Hodgkin's disease and non-Hodgkin's lymphomas, small cell and non-small cell lung cancer, cancers of the breast, ovaries, stomach, thyroid, and bladder, osteogenic and soft tissue sarcomas, and malignant melanoma. The 1 5 side effects include nausea, vomiting, alopecia, rnyelosuppression, and dose-dependent cardiotoxicity (>550 mg/m2).
IZelyveld, LJ~P 4,625,019, describes an autopolyrnerized antitumor agent, that is, daunorubicin is brought in contact with a bifunctional crosslinking agent, such as glutaraldehyde. A form of 2 0 polymeric product is obtained, which is insoluble in aqueous media but which, on being resuspended in an aqueous medium in the absence of glutaraldehyde, gradually releases the antitumor agent in a soluble farm. This, method mainly consist of mixing together daunorubicin, an antibody and glutaraldehyde, which can combine in 2 5 three different ways. The conjugates obtained can be any of the followings:
2~2~.~~~
TITLE OE THE INVENTION
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent.
BACKGROUND OI~ THE IN~IENTION
Chemotherapeutic agents currently used for antitumour therapy are selected for their toxicity towards rapidly proliferating cells. Most of them cause undesirable systemic effects such as cardiac or renal toxicity, marrow aplasia, alopecia, nausea and vomiting.
During the last few years, many authors have tried to eliminate these 1 0 side effects by increasing the availability of the drug to the tumour site. Enzymes, radioisotopes, DNA, toxins, various macxomolecules, and antibodies against fibrin or against tumour-specific surface antigens were bound to drugs in an attempt to increase the selectivity of the chemotherapeutic agents, or to decrease their toxic effects on 1 5 normal cells ~Rubens R.D., hancet, 2 1974, pp.498-499; Gregoriadis G.
et al., Res. Commun.Chem. 1'athol. Pharm., TO, 1977, pp.351-362).
The targeting of drugs to a tumour by antibodies to surface antigens may have considerable implications by increasing the therapeutic index.
2 0 It is recognized that the ideal antineopiastic drug would destroy cancer cells without adverse effects or toxicities on normal cells, but no such drug exists. I-Towever, despite the narrow therapeutic index of many drugs, treatment and even cure are possible in some patients.
Dactinomycin, doxorubicin and daunorubicin are all given 2 5 rapidly intravenously and all cause tissue necrosis if extravasation occurs. When doxorubicin and daunorubicin are given rapidly intravenously, there is rapid dispersement throughout tissues and plasma. The r7 t1/2 is 30 min, with detectable plasma levels of doxorubicin up to 15 h. Both doxorubicin and daunorubicin are extensively metabolized by the liver, yielding active and inactive metabolites.
Dactinomycin, doxorubicin and daunorubicin have limited antitumor activity. Dactinomycin is effective in testicular carcinoma and sarcomas. Daunorubicin is effective in treating acute leukemia.
1 0 In contrast, doxorubicin is one of the most active antineoplastics ever identified. In fact it is used to treat acute leukemia, Hodgkin's disease and non-Hodgkin's lymphomas, small cell and non-small cell lung cancer, cancers of the breast, ovaries, stomach, thyroid, and bladder, osteogenic and soft tissue sarcomas, and malignant melanoma. The 1 5 side effects include nausea, vomiting, alopecia, rnyelosuppression, and dose-dependent cardiotoxicity (>550 mg/m2).
IZelyveld, LJ~P 4,625,019, describes an autopolyrnerized antitumor agent, that is, daunorubicin is brought in contact with a bifunctional crosslinking agent, such as glutaraldehyde. A form of 2 0 polymeric product is obtained, which is insoluble in aqueous media but which, on being resuspended in an aqueous medium in the absence of glutaraldehyde, gradually releases the antitumor agent in a soluble farm. This, method mainly consist of mixing together daunorubicin, an antibody and glutaraldehyde, which can combine in 2 5 three different ways. The conjugates obtained can be any of the followings:
2~2~.~~~
1- 33% Antibody - glutaraldehyde - Daunorubicin 2- 33% Antibody - glutaraldehyde - Antibody 3- 33% Daunorubicin - glutaraldehyde - Daunorubicin and which only the Antibody - glutaraldehyde - Daunorubicin conjugate is active. Furthermore, these three possible conjugates can be linked together by the excess glutaraldehyde in solution to form an agglomerate, which makes it difficult to isolate the active conjugate.
This is the reason why we refer to an autopolymerized antitumor agent in this patent.
1 0 This method is not readily reproducible and give an unstable conjugate product. Unfortunately, this autopolymerized antitumor agent has the disadvantage of being insoluble in water and thus looses its specific activity against tumor cells. This insoluble product can not be used intravenously far a systemic treatment since it is taken up .
1 5 by phagocytic cells such as rnonocytes, macrophage or cells. This product is not very stable and do not have a very long shelf life.
The pxoblems posed by the administration of antitumor agents or cytostatic agents are made particularly difficult by the nature of the illness and vexy high toxicity of the active products.
2 0 It would be highly desirable if the efficiency of the use of arttitumor agents could be improved so as to allow their gradual release in the organism, while elearly improving their efficiency and the patient's eomfort. It would also be highly desirable, if there could be such an antitumor agent which would be easily produce, 2 S substantially pure, which would also not have a tendency to polymerized and hence have a long shelf life.
This is the reason why we refer to an autopolymerized antitumor agent in this patent.
1 0 This method is not readily reproducible and give an unstable conjugate product. Unfortunately, this autopolymerized antitumor agent has the disadvantage of being insoluble in water and thus looses its specific activity against tumor cells. This insoluble product can not be used intravenously far a systemic treatment since it is taken up .
1 5 by phagocytic cells such as rnonocytes, macrophage or cells. This product is not very stable and do not have a very long shelf life.
The pxoblems posed by the administration of antitumor agents or cytostatic agents are made particularly difficult by the nature of the illness and vexy high toxicity of the active products.
2 0 It would be highly desirable if the efficiency of the use of arttitumor agents could be improved so as to allow their gradual release in the organism, while elearly improving their efficiency and the patient's eomfort. It would also be highly desirable, if there could be such an antitumor agent which would be easily produce, 2 S substantially pure, which would also not have a tendency to polymerized and hence have a long shelf life.
~(JMMAR~( ~E TIDE IIOIVEN~I0141 Surprisingly and in accordance with the present invention, there is provided antitumor agents which overcome the drawback of the prior art. The already reported techniques for coupling anthracycline drugs to antibody either cause polymerization or yield a product which is considerably less active than the free drug. ~LJsing the method of the present invention, a wide variety of monoclonal antibodies specific for various tumors are conjugated to other carriers that could be used for drug targeting.
l 0 In accordance with the present invention, there is provided novel compounds of the formula I;
R -IC- (CH2 )3 - C, -M ;
wherein, - M is selected from the following group consisting of an 1 S hydrogen atom , a peptide residue and a protein residue linked to the carbon atom via the amino residue of ~-lysine present therein, and R is an antitumor agent residue such as daunorubicin, doxorubicin, or epirubicin.
When M is a protein, it can be an antibody which is used to 2 0 target the antitumor agent to the malignant cells and thereby improving the conditions of such anti-cancer treatments.
The compounds of the present invention are easily produced and are devoid of significant polymerization since they are substantially pure. The compounds of the present invention have the ability to provide the full pharmacological activity of the antitumor agent without the disadvantage normally associated with said antitumor agent. The improved coupling procedure of the present invention involved in the production of these compounds of farmula I is readily reproducible and the resulting compounds are substiantially stable at 25°C.
Other advantages of the present invention will be readily illustrated by referring to the following description.
Ih1 THE DIiAi~VIIyIGS
1 0 Figure 1 shows the Cytotoxicity of Equimolar Concentrations of Free or Monoclonal AntiCEA Bound Daunorubicin on Human Colon Adenocarcinoma Cells (LoVo).
Figure 2 shows the Cytotoxicity of Equimolar Concentrations of Free or Monoelonal AntiCEA Bound Daunorubicin on Human MG-1 5 3 Osteosarcoma Cells.
Figure 3 shows the Cytotoxicity of Equimolar Concentrations of Free or Monoclonal AntiCEA Bound Daunorubicin on Human Amnion Cells.
Figure 4 shows the Cytotoxicity of Equimolar Concentrations of 2 0 Free or Monoclonal AntiCEA Bound Daunorubicin on Human Embryonic Intestine Cells (CCL-6).
~a~~.9~2 DETAILED DESCRIPTION OF TI-iE INVENTION
The compounds o'. the present invention correspond to the general formula I:
R -IC- (CHI )3 - CI -M I
wherein R and M are as defined previously.
The products of the present invention are prepared as follows:
An antitumor agent R is first reacted with an excess of glutaraldehyde, which gives an intermediate R-glutaraldehyde of formula (I), wherein M is an hydrogen atom. This intermediate 1 0 reaction product has a terminal aldehyde group.
The intermediate reaction product is extracted with a solvent such as dichlorornethane to yield a purified activated R-glutaraldehyde having a terminal aldehyde group. This activated R-glutaraldehyde product is then dried on Na-sulfate and dissolved in a 1 5 solvent such as dimethylsulfoxide (DMSO) and then is reacted with an ~-lysine containing protein or peptide to yield tile final conjugate R-glutaraldehyde-M. This conjugate is finally obtained by a simple gel filtration.
Results obtained with activated daunorubiein using this new 2 0 procedure show that the pharmacological activity of the drug could be saved while limiting the undesirable polymerization of the antibody normally encountered with bivalent coupling agents. This procedure is easy and reproducible and reagents are readily available commercially. The activation of the drug can be accomplished in less ~2~,~~2 than 2 hours and the activated drug remains active for a week at room temperature.
It has also been found that the activated drug can retain its activity for many months if stored in liquid nitrogen.
All the improvements of the R-glutaraldehyde-M conjugate of the present invention can be seen from the following reaction schemes. The method of the present invention is readily reproducible and gives a R-glutaraldehyde-M conjugate, which does not have a tendency to polymerize.
1 0 COUPLING OF ANTITUMOR AGENT (R) TO PROTEIN (M) OLD METHOD PRESENT' METHOD
R + M R + Glutaraldehyde ~, Glutaraldehyde Separation of R-glutaraldehyde-M R-glutaraldehyde f 5 conjugate by gel filtration Diehloromethane extraction R-glutaraldehyde-M Purified activated R-glutaraldehyde Dry on Na-sulfate 2 0 Dissolve in DMSO
Activated R-glutaraldehyde + Peptide or Protein Separation by gel filtration R-glutaraidehyde-M
l 0 In accordance with the present invention, there is provided novel compounds of the formula I;
R -IC- (CH2 )3 - C, -M ;
wherein, - M is selected from the following group consisting of an 1 S hydrogen atom , a peptide residue and a protein residue linked to the carbon atom via the amino residue of ~-lysine present therein, and R is an antitumor agent residue such as daunorubicin, doxorubicin, or epirubicin.
When M is a protein, it can be an antibody which is used to 2 0 target the antitumor agent to the malignant cells and thereby improving the conditions of such anti-cancer treatments.
The compounds of the present invention are easily produced and are devoid of significant polymerization since they are substantially pure. The compounds of the present invention have the ability to provide the full pharmacological activity of the antitumor agent without the disadvantage normally associated with said antitumor agent. The improved coupling procedure of the present invention involved in the production of these compounds of farmula I is readily reproducible and the resulting compounds are substiantially stable at 25°C.
Other advantages of the present invention will be readily illustrated by referring to the following description.
Ih1 THE DIiAi~VIIyIGS
1 0 Figure 1 shows the Cytotoxicity of Equimolar Concentrations of Free or Monoclonal AntiCEA Bound Daunorubicin on Human Colon Adenocarcinoma Cells (LoVo).
Figure 2 shows the Cytotoxicity of Equimolar Concentrations of Free or Monoelonal AntiCEA Bound Daunorubicin on Human MG-1 5 3 Osteosarcoma Cells.
Figure 3 shows the Cytotoxicity of Equimolar Concentrations of Free or Monoclonal AntiCEA Bound Daunorubicin on Human Amnion Cells.
Figure 4 shows the Cytotoxicity of Equimolar Concentrations of 2 0 Free or Monoclonal AntiCEA Bound Daunorubicin on Human Embryonic Intestine Cells (CCL-6).
~a~~.9~2 DETAILED DESCRIPTION OF TI-iE INVENTION
The compounds o'. the present invention correspond to the general formula I:
R -IC- (CHI )3 - CI -M I
wherein R and M are as defined previously.
The products of the present invention are prepared as follows:
An antitumor agent R is first reacted with an excess of glutaraldehyde, which gives an intermediate R-glutaraldehyde of formula (I), wherein M is an hydrogen atom. This intermediate 1 0 reaction product has a terminal aldehyde group.
The intermediate reaction product is extracted with a solvent such as dichlorornethane to yield a purified activated R-glutaraldehyde having a terminal aldehyde group. This activated R-glutaraldehyde product is then dried on Na-sulfate and dissolved in a 1 5 solvent such as dimethylsulfoxide (DMSO) and then is reacted with an ~-lysine containing protein or peptide to yield tile final conjugate R-glutaraldehyde-M. This conjugate is finally obtained by a simple gel filtration.
Results obtained with activated daunorubiein using this new 2 0 procedure show that the pharmacological activity of the drug could be saved while limiting the undesirable polymerization of the antibody normally encountered with bivalent coupling agents. This procedure is easy and reproducible and reagents are readily available commercially. The activation of the drug can be accomplished in less ~2~,~~2 than 2 hours and the activated drug remains active for a week at room temperature.
It has also been found that the activated drug can retain its activity for many months if stored in liquid nitrogen.
All the improvements of the R-glutaraldehyde-M conjugate of the present invention can be seen from the following reaction schemes. The method of the present invention is readily reproducible and gives a R-glutaraldehyde-M conjugate, which does not have a tendency to polymerize.
1 0 COUPLING OF ANTITUMOR AGENT (R) TO PROTEIN (M) OLD METHOD PRESENT' METHOD
R + M R + Glutaraldehyde ~, Glutaraldehyde Separation of R-glutaraldehyde-M R-glutaraldehyde f 5 conjugate by gel filtration Diehloromethane extraction R-glutaraldehyde-M Purified activated R-glutaraldehyde Dry on Na-sulfate 2 0 Dissolve in DMSO
Activated R-glutaraldehyde + Peptide or Protein Separation by gel filtration R-glutaraidehyde-M
Cell Lines The cell lines were only used as targets to show that the conjugate can be directed to the desired sites. As cell lines there may be used : human embryonic intestine cells (CCL-6), human amnion cells (CCL-25), human osteosarcoma cells (CRL-1427), human ovarian carcinoma (CRL-1572), human hepatoma cells (HS-703-T), Mause melanoma (CRL-6323) and LoVo human adenocarcinoma cells (CCL-229). These cell lines are readily available from the American Type Culture Callection under the numbers shown in 'brackets, except for 1 0 the human hepatoma (HS-703-T) which can be obtained from Dr.
Williams C. Parks at Michigan State University, East Lansing, Michigan, U.S.A.
The LoVo cells produce carcinoembryonic antigen in culture.
The human ovarian carcinoma cells produce alphafoetoprotein. All cell lines are routinely cultured in RPMI-1640~ medium supplemented with 10% foetal bovine serum and 100 ug per ml of streptomycin and 100 ug per ml of penicillin.
Antibody and Peptide The antibadies and peptides were only used in order to direct 2 0 the conjugates to the desired cell lines used. The antibodies were obtained through standard monoclonal antibody production procedures using the above-mentioned cell lines. As antibodies there may be used . anti-carcinoembryonic manoclonal, anti-carcinaembxyonic polyclonal antibody, anti-alphafetoprotein 2 5 monoclonal, anti-alphafetoprotein polyclonal antibody, anti-embryonic pre-albumine monoclonal antibody. As a peptide there may be used: human transferin and lys-bombesin.
°In vitro' Cytotoxicity In oxdex to evaluate the efficiency of the compounds of formula ~I), the following procedure is used and other methods of in vitro cytotoxicity could have been used.
The conjugate solution is adjusted to 2% bovine serum albumin in 0,05 M ammonium acetate buffer. The solution is then freeze dried and gamma radiated wtih 16 000 rads. Before the assay, 1 0 the dry conjugate is taken up in Dulbecco~ phosphate buffer saline and added at various concentrations to culture medium.
The cytotoxic activity of daunorubicin and antiCEA conjugate on the various cell lines is evaluated by inhibition of colony formation as described in Fmond et al., Anthracyclines, 1983, Ed. G.
1 5 Mathe, Masson Publish N.Y., U.S.A., 105. Briefly, 2,500 cells are added to 1 ml of RPMI 1640 medium supplemented with 10% foetal bovine serum in 24 well plates: Cells are allowed to attach for 24 hours, medium is removed and replaced by various test compounds diluted in growth medium. The tested drugs are incubated with the 2 0 cells for four days in complete growth medium. Each assay is performed in quadruplicate.
After the growth period, medium is decanted, colonies are fixed with. formol and stained with crystal violet as reported in Belles-Isles et al., Brit. J. Cancer, 1980, 41 840.
~0~~.~42 Following the procedures of the present invention, the following compounds have been obtained:
3t M
_ - hydrogen - daunorubicin 5 - doxorubicin - hydrogen - epirubicin - hydrogen - daunorubicin - antiCEA
- doxorubicin - antiCEA
- epirubicin - antiCEA
1 0 - daunorubicin - antiAFP
- doxorubicin - antiAFP
- epirubicin - antiAFP
- daunorubicin - antiCA-225 - doxorubicin - antiCA-125 1 5 - epirubicin - antiCA-125 - daunorubicin -lys-bombesin - doxorubicin -lys-bombesin - epirubicin -lys-bombesin - daunorubicin - antiEPA
2 0 - doxorubicin - antiEPA
epirubicin - antiEPA
Cytotoxicity of conjugates Results obtained b~ inhibition of colony formation on the cytotoxicity of free or antiCEA bound daunorubicin are shown on 2 5 Figures 1 to 4. For any cell line used, we find a dose-response relationship is determined. The cytotoxicity of antiCEA conjugate for LoVo cells is 250 ng/ml as compared to 400 ng/ml for the free drug (Figure 1); the cytotoxicity of antiCEA conjugate for human osteosarcoma (CRL-1427) cells is significantly higher than the one of 3 0 the free drug (Figure 2).
The conjugate is more cytotoxic for normal human amnion cells and human embryonic intestine (CCL-6) than the free drug (Figures 3 and 4).
'The LDSQ (lethal dose to kill 50% of the malignant cells) of free and bound antitumor agent fox the various cell lines is reported in Table 1 below.
TABLE ~
C~~,otoxicitx 1LD5~g _/ml) of Free and Bound Daunorubicin For the 'VariousCell Lanes %a i.D~
CELL LINES FREE DRUG CONJUGATE decrease daunorubicin Anti-CEA-daunorubicin human colon adenocarcinoma 250 37 human osteosarcoma 75 24 68 human amnion 77 29 62 1 0 human embryonic intestine142 83 42 Anti-EPA-datinorubicin human osteosarcoma 160 91 43 Anti-alphafoetoprotein-daunorubicin 1 $ human amnion 57 49 24 human hepatoma 41 31 24 human osteosarcoma 30 12 60 It can be seen that the dosage required to inhibit 50% of the malignant Bells for the compounds of the present invention is much 2 0 lower than for the free drug itself. The lowex the LDSO the better the drug targetting is and hence less sides effects are observed. The LD~o % decrease is found between 14% to &8% depending on the drug or the cell line used. Compounds with such an ability to target antifumor agents without substantially lowering their pharmaceutical 2 5 activity were long waited for.
2~21~4~
The method of the present invention for coupling an anti-tumor agent to an antibody provides molar ratios of anti-tumor to antibody varying from 0.5:1 to '13:1 as desired. The preferred molar ratios for coupling anti-tumor agent to antibody being 5:1 to 7:1.
The glutaraldehyde being used is a 25% aqueous solution of glutaraldehyde in a stoichiometric amount.
The present invention will be more readily understood by referring to the following Examples which are given to illustrate the invention rather than to limit its scope.
1 0 Example I
A- Glaxtaraldehyde Activated Daunorubicin One mg of daunorubicin hydrochloride is dissolved in 4 ml of 0.05 M phosphate buffer at pH 7.5 and 60 ul of 25% glutaraldehyde is added (grade II, Sigma Chemicals, St. Louis, USA). The mixture is 1 5 stirred for 15 minutes at room temperature and 1 ml of distilled water is added. The mixture is extracted twice with 5 m1 of dichloromethane; the organic phases are pooled and treated four times with an equal volume of 5% lVaHC03 solution containing 15%
glycine: The organic phase is dried with anhydrous sodium sulphate, 2 0 filtered, and the solvent is evaporated under a stream of nitrogen at room temperature. The dried product is taken in a minimum volume of dimethylsulfoxide (DMSO).
~02~.~~~
1%
The coefficient of extinction is E 495 = 176 in 10% dimethyl-sulfoxide in 0.05 M phosphate buffer at pH 7.2 for the activated derivative.
B-Antibody Purification Monoclonal antiCEA 341-~6-36 antigen is purified from mouse ascitic fluid by precipitation with 50°lo saturated ammonium sulphate.
The antibody precipitate is dissolved in the original volume of phosphate buffer at pH 7.2 and dialyzed for 24 hours at 4°C against 1 0 Dulbeccoo phosphate buffer saline. The antibody concentration is then measured with the Lowry method (Tsukada, Kato, Umemoto, Takeda, Hara and Hirai, H:J. Nat. Cancer Inst.,19$4, 73, 721).
C- Conjugation Procedure The glutaraldehyde activated daunorubicin derivative is dissolved 1 5 in 100 ul of dimethylsulfoxide and added with stirring to 500 ug of monoclonal antiCEA antibody dissolved in 400 ul of phosphate buffer. The reaction mixture is incubated for 60 minutes at 37°C and the protein conjugate is separated on Sephadex G-25~ on a PD-10~
column (Pharmacia, Canada), equilibrated with 0.05 M ammonium 2 0 acetate at pH 6.5 containing 0.3 rnM glycine. The conjugate appeaxs in the void volume of the column. ~'lte conjugation ratio is determined by spectrophotometry taking an %D 1%Q
E 495 =176 for daunorubicin and E 28p = 4.5 for monoclonal antibody.
2 5 There is obtained the Daunorubicin- Glutaraldehyde -AntiCE A
monoclonal antibody conjugate.
Exaxn lp a II
Proceding as in example I but using antiAFP antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiAFP- daunorubicin conjugate.
$ Example III
Proceding as in example I but using antiCA-125 antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiCA-125- daunorubicin conjugate.
Example IV
1 0 Proceding as in example I but using antiEPA antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiEPA- daunorubicin conjugate.
Example V
Proceding as in example I but using lys-bombesin antibody 1 5 instead of the antiCEA monoclonal antibody in step B, there is obtained lys-bombesin- daunorubicin conjugate.
Example "VI
Proceding as in example I but using doxorubicin instead of daunorubicin in step B, there is obtained antiCEA-doxorubicin 2 0 conjugate.
Exam ~ VII
Proceding as in example II but using doxorubicin instead of daunorubicin in step B, there is obtained antiAFP-doxorubicin conjugate.
Example VIII
Proceding as in example III but using doxorubicin instead of daunorubicin in step B, there is obtained antiCA-125-doxorubicin conjugate.
Example IX
1 0 Proceding as in example IV but using doxorubicin instead of daunorubicin in step B, there is obtained antiEPA-doxorubicin conjugate.
Example X
Proceding as in example V but using doxorubicin instead of 1 5 daunorubicin in step B, there is obtained lys-bombesin-doxorubicin conjugate.
Examph XI
Proceding as in example I but using epirubicin instead of daunorubicin in step B, there is obtained antiCEA-epirubicin 2 0 conjugate.
Example XII
Proceding as in example II but using epirubicin instead of daunorubicin in step B, there is obtained antiAFP-epirubicin conjugate.
Exam Ip a ?CIIi Proceding as in example III but using epirubicin instead of daunorubicin in step B, there is obtained antiCA-125-epirubicin conjugate.
Example XIV
Proceding as in example iV but using epirubicin instead of daunorubicin in step B, there is obtained antiEPA-epirubicin conjugate.
Example %V
I 0 Proceding as in example V but using epirubicin instead of daunorubicin in step B, there is obtained lys-bombesin-epirubicin conjugate.
Williams C. Parks at Michigan State University, East Lansing, Michigan, U.S.A.
The LoVo cells produce carcinoembryonic antigen in culture.
The human ovarian carcinoma cells produce alphafoetoprotein. All cell lines are routinely cultured in RPMI-1640~ medium supplemented with 10% foetal bovine serum and 100 ug per ml of streptomycin and 100 ug per ml of penicillin.
Antibody and Peptide The antibadies and peptides were only used in order to direct 2 0 the conjugates to the desired cell lines used. The antibodies were obtained through standard monoclonal antibody production procedures using the above-mentioned cell lines. As antibodies there may be used . anti-carcinoembryonic manoclonal, anti-carcinaembxyonic polyclonal antibody, anti-alphafetoprotein 2 5 monoclonal, anti-alphafetoprotein polyclonal antibody, anti-embryonic pre-albumine monoclonal antibody. As a peptide there may be used: human transferin and lys-bombesin.
°In vitro' Cytotoxicity In oxdex to evaluate the efficiency of the compounds of formula ~I), the following procedure is used and other methods of in vitro cytotoxicity could have been used.
The conjugate solution is adjusted to 2% bovine serum albumin in 0,05 M ammonium acetate buffer. The solution is then freeze dried and gamma radiated wtih 16 000 rads. Before the assay, 1 0 the dry conjugate is taken up in Dulbecco~ phosphate buffer saline and added at various concentrations to culture medium.
The cytotoxic activity of daunorubicin and antiCEA conjugate on the various cell lines is evaluated by inhibition of colony formation as described in Fmond et al., Anthracyclines, 1983, Ed. G.
1 5 Mathe, Masson Publish N.Y., U.S.A., 105. Briefly, 2,500 cells are added to 1 ml of RPMI 1640 medium supplemented with 10% foetal bovine serum in 24 well plates: Cells are allowed to attach for 24 hours, medium is removed and replaced by various test compounds diluted in growth medium. The tested drugs are incubated with the 2 0 cells for four days in complete growth medium. Each assay is performed in quadruplicate.
After the growth period, medium is decanted, colonies are fixed with. formol and stained with crystal violet as reported in Belles-Isles et al., Brit. J. Cancer, 1980, 41 840.
~0~~.~42 Following the procedures of the present invention, the following compounds have been obtained:
3t M
_ - hydrogen - daunorubicin 5 - doxorubicin - hydrogen - epirubicin - hydrogen - daunorubicin - antiCEA
- doxorubicin - antiCEA
- epirubicin - antiCEA
1 0 - daunorubicin - antiAFP
- doxorubicin - antiAFP
- epirubicin - antiAFP
- daunorubicin - antiCA-225 - doxorubicin - antiCA-125 1 5 - epirubicin - antiCA-125 - daunorubicin -lys-bombesin - doxorubicin -lys-bombesin - epirubicin -lys-bombesin - daunorubicin - antiEPA
2 0 - doxorubicin - antiEPA
epirubicin - antiEPA
Cytotoxicity of conjugates Results obtained b~ inhibition of colony formation on the cytotoxicity of free or antiCEA bound daunorubicin are shown on 2 5 Figures 1 to 4. For any cell line used, we find a dose-response relationship is determined. The cytotoxicity of antiCEA conjugate for LoVo cells is 250 ng/ml as compared to 400 ng/ml for the free drug (Figure 1); the cytotoxicity of antiCEA conjugate for human osteosarcoma (CRL-1427) cells is significantly higher than the one of 3 0 the free drug (Figure 2).
The conjugate is more cytotoxic for normal human amnion cells and human embryonic intestine (CCL-6) than the free drug (Figures 3 and 4).
'The LDSQ (lethal dose to kill 50% of the malignant cells) of free and bound antitumor agent fox the various cell lines is reported in Table 1 below.
TABLE ~
C~~,otoxicitx 1LD5~g _/ml) of Free and Bound Daunorubicin For the 'VariousCell Lanes %a i.D~
CELL LINES FREE DRUG CONJUGATE decrease daunorubicin Anti-CEA-daunorubicin human colon adenocarcinoma 250 37 human osteosarcoma 75 24 68 human amnion 77 29 62 1 0 human embryonic intestine142 83 42 Anti-EPA-datinorubicin human osteosarcoma 160 91 43 Anti-alphafoetoprotein-daunorubicin 1 $ human amnion 57 49 24 human hepatoma 41 31 24 human osteosarcoma 30 12 60 It can be seen that the dosage required to inhibit 50% of the malignant Bells for the compounds of the present invention is much 2 0 lower than for the free drug itself. The lowex the LDSO the better the drug targetting is and hence less sides effects are observed. The LD~o % decrease is found between 14% to &8% depending on the drug or the cell line used. Compounds with such an ability to target antifumor agents without substantially lowering their pharmaceutical 2 5 activity were long waited for.
2~21~4~
The method of the present invention for coupling an anti-tumor agent to an antibody provides molar ratios of anti-tumor to antibody varying from 0.5:1 to '13:1 as desired. The preferred molar ratios for coupling anti-tumor agent to antibody being 5:1 to 7:1.
The glutaraldehyde being used is a 25% aqueous solution of glutaraldehyde in a stoichiometric amount.
The present invention will be more readily understood by referring to the following Examples which are given to illustrate the invention rather than to limit its scope.
1 0 Example I
A- Glaxtaraldehyde Activated Daunorubicin One mg of daunorubicin hydrochloride is dissolved in 4 ml of 0.05 M phosphate buffer at pH 7.5 and 60 ul of 25% glutaraldehyde is added (grade II, Sigma Chemicals, St. Louis, USA). The mixture is 1 5 stirred for 15 minutes at room temperature and 1 ml of distilled water is added. The mixture is extracted twice with 5 m1 of dichloromethane; the organic phases are pooled and treated four times with an equal volume of 5% lVaHC03 solution containing 15%
glycine: The organic phase is dried with anhydrous sodium sulphate, 2 0 filtered, and the solvent is evaporated under a stream of nitrogen at room temperature. The dried product is taken in a minimum volume of dimethylsulfoxide (DMSO).
~02~.~~~
1%
The coefficient of extinction is E 495 = 176 in 10% dimethyl-sulfoxide in 0.05 M phosphate buffer at pH 7.2 for the activated derivative.
B-Antibody Purification Monoclonal antiCEA 341-~6-36 antigen is purified from mouse ascitic fluid by precipitation with 50°lo saturated ammonium sulphate.
The antibody precipitate is dissolved in the original volume of phosphate buffer at pH 7.2 and dialyzed for 24 hours at 4°C against 1 0 Dulbeccoo phosphate buffer saline. The antibody concentration is then measured with the Lowry method (Tsukada, Kato, Umemoto, Takeda, Hara and Hirai, H:J. Nat. Cancer Inst.,19$4, 73, 721).
C- Conjugation Procedure The glutaraldehyde activated daunorubicin derivative is dissolved 1 5 in 100 ul of dimethylsulfoxide and added with stirring to 500 ug of monoclonal antiCEA antibody dissolved in 400 ul of phosphate buffer. The reaction mixture is incubated for 60 minutes at 37°C and the protein conjugate is separated on Sephadex G-25~ on a PD-10~
column (Pharmacia, Canada), equilibrated with 0.05 M ammonium 2 0 acetate at pH 6.5 containing 0.3 rnM glycine. The conjugate appeaxs in the void volume of the column. ~'lte conjugation ratio is determined by spectrophotometry taking an %D 1%Q
E 495 =176 for daunorubicin and E 28p = 4.5 for monoclonal antibody.
2 5 There is obtained the Daunorubicin- Glutaraldehyde -AntiCE A
monoclonal antibody conjugate.
Exaxn lp a II
Proceding as in example I but using antiAFP antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiAFP- daunorubicin conjugate.
$ Example III
Proceding as in example I but using antiCA-125 antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiCA-125- daunorubicin conjugate.
Example IV
1 0 Proceding as in example I but using antiEPA antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiEPA- daunorubicin conjugate.
Example V
Proceding as in example I but using lys-bombesin antibody 1 5 instead of the antiCEA monoclonal antibody in step B, there is obtained lys-bombesin- daunorubicin conjugate.
Example "VI
Proceding as in example I but using doxorubicin instead of daunorubicin in step B, there is obtained antiCEA-doxorubicin 2 0 conjugate.
Exam ~ VII
Proceding as in example II but using doxorubicin instead of daunorubicin in step B, there is obtained antiAFP-doxorubicin conjugate.
Example VIII
Proceding as in example III but using doxorubicin instead of daunorubicin in step B, there is obtained antiCA-125-doxorubicin conjugate.
Example IX
1 0 Proceding as in example IV but using doxorubicin instead of daunorubicin in step B, there is obtained antiEPA-doxorubicin conjugate.
Example X
Proceding as in example V but using doxorubicin instead of 1 5 daunorubicin in step B, there is obtained lys-bombesin-doxorubicin conjugate.
Examph XI
Proceding as in example I but using epirubicin instead of daunorubicin in step B, there is obtained antiCEA-epirubicin 2 0 conjugate.
Example XII
Proceding as in example II but using epirubicin instead of daunorubicin in step B, there is obtained antiAFP-epirubicin conjugate.
Exam Ip a ?CIIi Proceding as in example III but using epirubicin instead of daunorubicin in step B, there is obtained antiCA-125-epirubicin conjugate.
Example XIV
Proceding as in example iV but using epirubicin instead of daunorubicin in step B, there is obtained antiEPA-epirubicin conjugate.
Example %V
I 0 Proceding as in example V but using epirubicin instead of daunorubicin in step B, there is obtained lys-bombesin-epirubicin conjugate.
Claims (6)
1. A method of preparing compounds of formula I
wherein M is selected from the group consisting of a peptide residue, and a protein residue linked to the carbon atom via an amino residue of .epsilon.-lysine present therein, and wherein R represents an anti-tumor agent residue, which comprises the steps of:
a) reacting said antitumor agent with glutaraldehyde;
b) purifying the activated product by extraction with dichloromethane; and c) reacting the drug-glutaraldehyde complex of step a) with a peptide or a protein M.
wherein M is selected from the group consisting of a peptide residue, and a protein residue linked to the carbon atom via an amino residue of .epsilon.-lysine present therein, and wherein R represents an anti-tumor agent residue, which comprises the steps of:
a) reacting said antitumor agent with glutaraldehyde;
b) purifying the activated product by extraction with dichloromethane; and c) reacting the drug-glutaraldehyde complex of step a) with a peptide or a protein M.
2. The method according to claim 1, wherein said antitumor agent is daunorubicin.
3. The method according to claim 1, wherein said antitumor agent is doxorubicin.
4. The method according to claim 1 wherein said antitumor agents is epirubicin.
5. The method according to claim 1, wherein said compound of formula I is antiCEA monoclonal antibody-daunorubicin conjugate.
6. The method according to claim 1, wherein M is a peptide selected from the group consisting of anti-carcinoembryonic monoclonal, anti-carcinoembryonic polyclonal antibody, anti-alphafetoprotein monoclonal, anti-alphafetoprotein polyclonal antibody, anti-embryonic pre-albumin monoclonal antibody, human transferrin and Lys3-bombesin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39192889A | 1989-08-10 | 1989-08-10 | |
| US391,928 | 1989-08-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2021942A1 CA2021942A1 (en) | 1991-02-11 |
| CA2021942C true CA2021942C (en) | 2001-04-10 |
Family
ID=23548555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002021942A Expired - Lifetime CA2021942C (en) | 1989-08-10 | 1990-07-25 | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA2021942C (en) |
| WO (1) | WO1991001757A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19636889A1 (en) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastic transferrin and albumin conjugates of cytostatic compounds from the group of the anthracyclines, alkylating agents, antimetabolites and cisplatin analogues and medicaments containing them |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5843926A (en) * | 1981-09-08 | 1983-03-14 | Suntory Ltd | Selective carcinostatic agent |
| GB2116979B (en) * | 1982-02-25 | 1985-05-15 | Ward Page Faulk | Conjugates of proteins with anti-tumour agents |
| JPS59134732A (en) * | 1983-01-21 | 1984-08-02 | Green Cross Corp:The | Preparation of fibronectin physiologically active substance complex |
| JPS59186924A (en) * | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | Antitumor agent bonded with human immunoglobulin |
| US4650675A (en) * | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
-
1990
- 1990-07-25 CA CA002021942A patent/CA2021942C/en not_active Expired - Lifetime
- 1990-08-09 WO PCT/CA1990/000251 patent/WO1991001757A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2021942A1 (en) | 1991-02-11 |
| WO1991001757A1 (en) | 1991-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5208323A (en) | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent | |
| US4699784A (en) | Tumoricidal methotrexate-antibody conjugate | |
| KR960015398B1 (en) | Anthracycline immunoconjugates having a novel linker and method for their production | |
| AU767394B2 (en) | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use | |
| ES2623017T3 (en) | Procedure for the preparation of an injectable drug formulation | |
| US4401592A (en) | Pharmaceutical composition having antitumor activity | |
| US4046722A (en) | Immunological materials | |
| US5004606A (en) | Non-covalent antibody-anthracycline immunocomplexes | |
| FI98197C (en) | A method of delivering a cytotoxic agent to tumor cells to prepare a useful antibody-enzyme conjugate | |
| PT99954B (en) | PROCESS FOR THE PREPARATION OF LABOR LIGACATION MOLECULES FOR ACIDS AND PHARMACEUTICAL COMPOSITIONS | |
| KR20160045146A (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
| BG63492B1 (en) | Methods for the preparation of monomer conjugates of kalicheamycin derivative/carrier | |
| EA010508B1 (en) | Method of targeting specific cells population using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates | |
| CA2128330A1 (en) | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light | |
| US5514794A (en) | Antibody-drug conjugates | |
| US4485093A (en) | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer | |
| KR20220038601A (en) | Camptothecin drug and antibody conjugate thereof | |
| CN113941007B (en) | Tandem double-drug linked assembly unit and application thereof | |
| KR900017597A (en) | Anthracycline conjugates with novel linkers and preparation methods thereof | |
| US5013547A (en) | Anticancer drug - antibody conjugates and method for preparing same | |
| CN114053426B (en) | Double-drug linked assembly unit and double-drug targeting connector-drug conjugate | |
| CA2101809A1 (en) | Cytotoxic drug conjugates for treatment of neoplastic diseases | |
| CA2021942C (en) | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent | |
| RU2106147C1 (en) | Conjugate of derived 14-bromidedaunorubicine with monoclonal antibody or its fragment with antitumor activity and specificity to the given tumor; pharmaceutical composition with antitumor activity | |
| Wilchek | Affinity therapy and polymer bound drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |